Home
/
Conditions
/ Hypertriglyceridemia
Metabolic Health
Schedule a Consultation
Hypertriglyceridemia
Hypertriglyceridemia is elevated serum triglycerides, and it is not primarily a dietary fat problem. It is a carbohydrate and insulin problem. The liver converts excess dietary carbohydrate, particularly fructose, into triglycerides through insulin-driven de novo lipogenesis. Elevated triglycerides are therefore a downstream marker of hyperinsulinemia and insulin resistance, not excessive fat consumption. Conventional management adds a fibrate or fish oil to a statin. Functional medicine identifies and treats the insulin-driven hepatic lipogenesis that produces the triglycerides in the first place.
Metabolic HealthInsulin-Driven LipogenesisReversible
~25%of US adults have triglycerides above 150 mg/dL
Insulinis the primary hormonal driver of hepatic triglyceride production
Reversiblewhen the carbohydrate and insulin drivers are identified and treated
← Back to Conditions
Condition: Hypertriglyceridemia | Category: Metabolic Health | Reviewed by: Brian Lamkin, DO
What Is Hypertriglyceridemia?
Hypertriglyceridemia is the elevation of serum triglycerides above physiologically optimal levels. Triglycerides are fatty acids packaged into very low-density lipoproteins (VLDL) by the liver and released into the bloodstream for energy transport and storage. When the liver produces more triglycerides than the body utilizes, serum levels rise. The primary driver of this overproduction in the majority of patients is not dietary fat intake. It is insulin-driven hepatic de novo lipogenesis: the conversion of excess dietary carbohydrate, particularly fructose, into triglycerides under the direct stimulation of elevated insulin.
This distinction matters because it changes the treatment paradigm completely. A patient placed on a low-fat diet for elevated triglycerides often substitutes carbohydrates for fat, increasing the substrate for hepatic lipogenesis and worsening the triglycerides. The effective intervention is carbohydrate quality and quantity reduction, not fat restriction. The triglyceride-to-HDL ratio is one of the most clinically useful markers of insulin resistance and atherogenic risk, providing more actionable information than LDL cholesterol alone.
Key principle: Triglycerides are made from carbohydrate, not dietary fat. The liver converts excess carbohydrate to triglycerides through de novo lipogenesis, a pathway that is directly activated by insulin. Reducing carbohydrate intake reduces the substrate; reducing insulin reduces the enzymatic drive. Together, these produce triglyceride reductions that typically exceed what fibrate or fish oil medication achieves.
Why It Matters
Cardiovascular and Metabolic Risk
- Elevated triglycerides with low HDL (the atherogenic dyslipidemia pattern) is a stronger cardiovascular predictor than elevated LDL cholesterol alone
- High triglycerides drive small dense LDL particle production, the most atherogenic LDL subtype, through cholesterol ester transfer protein (CETP) mediated lipid exchange
- The triglyceride/HDL ratio above 3.0 correlates strongly with insulin resistance, hepatic steatosis, and small dense LDL predominance
- Severe hypertriglyceridemia (above 500 mg/dL) increases risk for acute pancreatitis, a medical emergency
Why Standard Treatment Falls Short
- Low-fat dietary advice worsens triglycerides: reducing fat while increasing carbohydrate provides more substrate for hepatic lipogenesis
- Statins have minimal triglyceride-lowering effect: they reduce LDL through HMG-CoA reductase inhibition but do not address hepatic de novo lipogenesis
- Fibrates and fish oil treat the downstream marker without addressing the insulin and carbohydrate mechanism producing the triglyceride elevation
- Fasting insulin is not measured: the metabolic driver producing the triglycerides is invisible to standard lipid panel interpretation
Common Symptoms
Metabolic
- Often asymptomatic until detected on routine lipid panel
- Abdominal weight gain (visceral fat) accompanying the metabolic pattern
- Post-meal fatigue from carbohydrate-driven glucose and insulin spikes
- Carbohydrate cravings from the insulin-glucose cycling
Associated Findings
- Low HDL accompanying the elevated triglycerides (atherogenic pattern)
- Elevated fasting glucose or prediabetic HbA1c
- Elevated liver enzymes from concurrent hepatic steatosis
- Xanthomas (yellowish fatty deposits under skin) in severe cases
Severe (above 500 mg/dL)
- Abdominal pain from pancreatitis risk
- Eruptive xanthomas on trunk and extremities
- Lipemia retinalis (visible on fundoscopic exam)
- Hepatomegaly from triglyceride-laden hepatocytes
Root Causes: A Functional Medicine Perspective
Conventional lipidology treats elevated triglycerides with medication or generic dietary advice. Functional medicine identifies and treats the metabolic mechanism producing the triglyceride elevation.
Insulin-Driven Hepatic De Novo Lipogenesis
Elevated fasting insulin activates the transcription factor SREBP-1c in the liver, which upregulates fatty acid synthase and acetyl-CoA carboxylase, the enzymes that convert acetyl-CoA (derived from carbohydrate metabolism) into fatty acids that are assembled into triglycerides and packaged into VLDL particles. This pathway is the primary source of elevated triglycerides in the metabolic syndrome population. HOMA-IR above 1.9 confirms the insulin resistance driving the process.
Fructose and the Hepatic Lipogenesis Pathway
Fructose is uniquely lipogenic because it bypasses the rate-limiting step of glycolysis (phosphofructokinase) and is metabolized almost exclusively by the liver, where it is channeled directly into de novo lipogenesis. High-fructose corn syrup, concentrated fruit juice, agave, and excessive whole fruit consumption provide substrate that the liver converts to triglycerides with exceptional efficiency. Fructose elimination is one of the single highest-impact dietary interventions for triglyceride reduction.
Thyroid Dysfunction and Hepatic Clearance
Thyroid dysfunction, particularly hypothyroidism, reduces hepatic lipase activity and LDL receptor expression, impairing the clearance of triglyceride-rich lipoproteins from the bloodstream. Even subclinical hypothyroidism (TSH elevated with normal free T4) can produce measurable triglyceride elevation. Thyroid evaluation is a required component of hypertriglyceridemia assessment.
Alcohol, Gut Dysbiosis, and Visceral Adiposity
Alcohol is metabolized by the liver through pathways that increase hepatic fat production. Gut dysbiosis produces metabolic endotoxemia that drives hepatic inflammatory signaling and lipogenesis. Visceral adiposity delivers free fatty acids directly to the liver through the portal circulation, providing additional substrate for triglyceride assembly.
Conventional vs Functional Medicine Approach
| Domain | Conventional Medicine | Functional Medicine |
|---|---|---|
| Assessment | Standard lipid panel; triglycerides as a secondary concern after LDL | Triglyceride/HDL ratio as a primary metabolic marker; fasting insulin, HOMA-IR, and particle analysis |
| Dietary | Low-fat diet (increases carbohydrate substrate for lipogenesis) | Low-glycemic nutrition with fructose elimination targeting the lipogenesis substrate |
| Pharmacology | Fibrate, high-dose fish oil, or niacin added to statin | Insulin reduction through dietary modification and berberine as first-line; omega-3 as adjunct |
| Root cause | Not systematically investigated | Insulin status, carbohydrate load, thyroid function, alcohol, and gut health evaluated |
Key Labs to Evaluate
Hypertriglyceridemia evaluation requires markers that identify the metabolic mechanism producing the triglyceride elevation, not just confirmation that triglycerides are elevated.
Fasting InsulinThe hormonal driver of hepatic de novo lipogenesis. Functional target below 5 uIU/mL.
→Triglycerides / HDL RatioRatio above 2.0 correlates with insulin resistance; above 3.0 confirms atherogenic dyslipidemia.
→HOMA-IRInsulin resistance index confirming the metabolic drive behind triglyceride production.
→HbA1cGlycemic control. Elevated HbA1c alongside high triglycerides confirms advanced metabolic dysfunction.
→hs-CRPInflammatory burden. Chronic inflammation compounds hepatic lipogenesis and cardiovascular risk.
→How to Interpret These Labs Together
Triglycerides 240 with HDL 38 and fasting insulin 17 is the classic insulin-driven atherogenic dyslipidemia pattern: ratio 6.3 (target below 2.0), confirming active hepatic lipogenesis from hyperinsulinemia. The triglycerides are a symptom; the insulin is the disease. Statin therapy will reduce LDL but will not reduce the triglycerides or raise the HDL because it does not address the insulin mechanism.
Triglycerides 180 with normal fasting insulin and elevated TSH identifies thyroid-mediated hypertriglyceridemia: impaired hepatic clearance of triglyceride-rich lipoproteins from hypothyroidism rather than overproduction from insulin-driven lipogenesis. Thyroid optimization is the primary intervention.
Triglycerides falling from 280 to 95 after carbohydrate reduction and time-restricted eating confirms the mechanism: removing the carbohydrate substrate and reducing the insulin drive eliminated the hepatic lipogenesis producing the triglycerides. This degree of reduction typically exceeds what fibrate medication achieves.
Common Patterns Seen in Patients
- The patient on a statin with persistent elevated triglycerides: LDL reduced from 160 to 92 on atorvastatin. Triglycerides unchanged at 220, HDL 42. The statin addressed LDL but the insulin-driven hepatic lipogenesis producing the triglycerides was never evaluated. Fasting insulin 19. Carbohydrate reduction and time-restricted eating reduced triglycerides to 78 and raised HDL to 56 within 10 weeks without additional medication.
- The patient told to eat less fat: Triglycerides 195. Advised to reduce dietary fat. Replaced fat calories with whole grain bread, oatmeal, and fruit. Triglycerides increased to 245 on repeat testing. The carbohydrate substitution provided more substrate for hepatic lipogenesis. Switching from low-fat to low-glycemic, adequate-fat nutrition reduced triglycerides to 88.
- The thin patient with high triglycerides: BMI 22, no visible excess weight. Triglycerides 210, HDL 44. Assumed to be genetic. Fasting insulin 13, diet history revealed high fruit juice, granola, and frequent snacking (6 eating occasions daily). Lean hyperinsulinemia with diet-driven hepatic lipogenesis. Meal consolidation to 3 meals in an 8-hour window and fructose elimination normalized triglycerides within 6 weeks.
- Persistent triglyceride elevation after alcohol cessation: Triglycerides 320 attributed to moderate alcohol use. Alcohol eliminated for 3 months, triglycerides dropped to 240 but plateaued. Residual insulin resistance (fasting insulin 15) maintaining hepatic lipogenesis independent of alcohol. Insulin sensitization produced the additional reduction alcohol cessation alone could not achieve.
Treatment and Optimization Strategy
Substrate and Driver Reduction
The treatment framework targets both the substrate (excess carbohydrate, particularly fructose) and the hormonal driver (insulin) that activates the hepatic lipogenesis pathway producing the triglycerides.
Dietary and Lifestyle Interventions
- Fructose elimination: remove high-fructose corn syrup, concentrated fruit juices, agave, and excessive whole fruit as the single highest-impact dietary change
- Low-glycemic, protein-anchored nutrition eliminating refined carbohydrates, processed grains, and added sugars
- Time-restricted eating (8 to 10 hour window) consolidating eating occasions to reduce total daily insulin exposure
- Resistance training 3 to 4 times weekly for GLUT-4 upregulation and insulin-independent glucose disposal
Clinical and Supplemental Support
- Omega-3 fatty acids (3 to 4g EPA+DHA daily) for VLDL production reduction and anti-inflammatory effect; pharmaceutical-grade fish oil for clinical triglyceride reduction
- Berberine (500mg twice daily) for AMPK activation, hepatic lipogenesis reduction, and insulin sensitization
- Thyroid optimization when hypothyroidism is contributing to impaired triglyceride clearance
- Alcohol reduction or elimination when alcohol contributes to hepatic triglyceride production
What Most Doctors Miss
- Triglycerides are a carbohydrate problem, not a fat problem: low-fat dietary advice increases the substrate for hepatic lipogenesis and frequently worsens triglycerides. Carbohydrate quality and quantity are the primary dietary targets.
- Fasting insulin is not measured: the hormonal driver activating hepatic triglyceride production is invisible to the standard lipid panel. Without fasting insulin, the mechanism cannot be identified or treated.
- The triglyceride/HDL ratio is more important than triglycerides alone: this ratio identifies insulin resistance and atherogenic dyslipidemia with greater clinical utility than isolated triglyceride or LDL values.
- Thyroid contribution is not assessed: hypothyroidism impairs triglyceride clearance and is a treatable, independent contributor that is frequently missed in lipid management.
When to Seek Medical Care
If your lipid panel shows elevated triglycerides, low HDL, or a triglyceride/HDL ratio above 2.0, or if your triglycerides have not responded to dietary changes or medication, a comprehensive metabolic evaluation is warranted. This is especially important if you have concurrent abdominal weight gain, prediabetes, or a family history of cardiovascular disease or type 2 diabetes.
At The Lamkin Clinic, hypertriglyceridemia evaluation includes fasting insulin, HOMA-IR, triglyceride/HDL ratio, HbA1c, full thyroid panel, hs-CRP, and adiponectin, reviewed as an integrated metabolic and cardiovascular profile.
Recommended Testing
Hypertriglyceridemia evaluation requires the metabolic markers that identify the insulin and carbohydrate mechanism producing the triglyceride elevation.
Foundational Labs
- Fasting Insulin
- HOMA-IR
- Triglycerides / HDL Ratio
- HbA1c
Advanced Assessment
- hs-CRP
- Adiponectin
- TSH, Free T3
- Fasting Glucose
- Omega-3 Index
Not sure which testing applies to you?
Explore All Testing Options →Frequently Asked Questions
Are high triglycerides caused by eating too much fat?
No. Elevated triglycerides are primarily caused by excess carbohydrate intake, particularly fructose and refined carbohydrates, not dietary fat. The liver converts excess carbohydrate into triglycerides through de novo lipogenesis, driven by insulin. Reducing carbohydrate intake produces more significant triglyceride reduction than reducing dietary fat.
What triglyceride level is concerning?
Standard guidelines classify below 150 mg/dL as normal. Functional medicine targets below 80 mg/dL as optimal and considers the triglyceride-to-HDL ratio (target below 2.0) as the more meaningful cardiovascular and metabolic marker. A ratio above 3.0 strongly correlates with insulin resistance and small dense LDL predominance.
Why are my triglycerides high if I eat healthy?
Many conventionally healthy foods are high-glycemic or high-fructose: fruit juice, whole grain bread, oatmeal with dried fruit, granola, and smoothies all stimulate substantial insulin secretion and provide carbohydrate substrate for hepatic lipogenesis. Meal frequency also matters: eating 5 to 6 times daily produces chronic insulin elevation.
Can exercise lower triglycerides?
Yes. Resistance training improves insulin sensitivity and reduces the insulin drive producing triglycerides. However, exercise alone produces modest reduction if dietary carbohydrate load and meal frequency remain unchanged. The combination of carbohydrate reduction, time-restricted eating, and resistance training produces the most significant improvement.
Should I take a statin for high triglycerides?
Statins primarily reduce LDL cholesterol and have limited triglyceride-lowering effect. Functional medicine targets the metabolic mechanism: reducing insulin through dietary modification and insulin sensitization produces triglyceride reductions that frequently exceed what medication achieves.
How The Lamkin Clinic Approaches Hypertriglyceridemia
Clinical Perspective
When I see elevated triglycerides, I am not looking at a lipid problem. I am looking at an insulin and carbohydrate problem that is expressing itself through the lipid panel. The first lab I order is fasting insulin, not a repeat lipid panel. When insulin comes back at 15 or 20, I know exactly why the triglycerides are elevated: the liver is converting carbohydrate to fat under insulin's instruction. Reduce the carbohydrate, reduce the insulin, and the triglycerides come down faster and more durably than any medication I could prescribe.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
At The Lamkin Clinic, hypertriglyceridemia evaluation begins with fasting insulin as the cornerstone metabolic marker, supported by HOMA-IR, triglyceride/HDL ratio, HbA1c, thyroid panel, and inflammatory markers. Treatment targets the metabolic mechanism: carbohydrate quality and quantity reduction, time-restricted eating, insulin sensitization, omega-3 supplementation, and thyroid optimization when indicated.
Related Conditions
Insulin ResistanceThe upstream metabolic driver of hepatic de novo lipogenesis producing triglycerides
→DyslipidemiaThe broader lipid disorder encompassing triglycerides, HDL, and LDL particle patterns
→Metabolic SyndromeHigh triglycerides with low HDL as a core diagnostic criterion
→Non-Alcoholic Fatty LiverHepatic steatosis from the same insulin-driven lipogenesis producing triglycerides
→Cardiovascular Disease RiskAtherogenic dyslipidemia from triglyceride-HDL imbalance driving cardiovascular events
→Type 2 DiabetesEnd-stage insulin resistance sharing the same hepatic lipogenesis mechanism
→Related Symptoms
Chronic FatiguePost-meal energy crashes from insulin-glucose cycling
→Obesity and Weight ManagementInsulin-driven fat storage accompanying the lipogenesis producing triglycerides
→Brain FogPostprandial glucose instability from the same insulin resistance driving triglycerides
→Sleep DisturbanceMetabolic dysfunction and nocturnal glucose instability disrupting sleep architecture
→Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Elevated triglycerides are a carbohydrate and insulin problem with an identifiable metabolic mechanism.
The Lamkin Clinic evaluates hypertriglyceridemia with fasting insulin, HOMA-IR, triglyceride/HDL ratio, and comprehensive metabolic assessment. Schedule a consultation for a root-cause lipid and metabolic evaluation.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.